Ordinary Index Rebalancing in the Solactive Global Genomics Immunology and Medical Revolution Index | November 2021

In the ordinary rebalance the following composition will be implemented effective open 01.12.2021:

10X GENOMICS INC
ABBVIE INC
AGILENT TECHNOLOGIES INC
ALLOGENE THERAPEUTICS INC
ALNYLAM PHARMACEUTICALS INC
ASTRAZENECA PLC
BEAM THERAPEUTICS INC
BIO-TECHNE CORP
BIOGEN INC
BIONANO GENOMICS INC
BIONTECH SE
BLUEBIRD BIO INC
BRISTOL-MYERS SQUIBB CO
CRISPR THERAPEUTICS AG
CUREVAC BV
EDITAS MEDICINE INC
ELI LILLY & CO
EXACT SCIENCES CORP
FATE THERAPEUTICS INC
GENMAB A/S
GILEAD SCIENCES INC
GUARDANT HEALTH INC
I-MAB
ILLUMINA INC
INNOVENT BIOLOGICS INC
INTELLIA THERAPEUTICS INC
INVITAE CORP
JOHNSON & JOHNSON
LONZA GROUP AG
MODERNA INC
NOVARTIS AG
NOVAVAX INC
OCUGEN INC
PACIFIC BIOSCIENCES OF CALIFORNIA INC
PERKINELMER INC
PFIZER INC
QIAGEN NV
REGENERON PHARMACEUTICALS
ROCHE HOLDING AG
SAMSUNG BIOLOGICS CO LTD
SANOFI SA
SAREPTA THERAPEUTICS INC
SK BIOPHARMACEUTICALS CO LTD
SORRENTO THERAPEUTICS INC
TG THERAPEUTICS INC
THERMO FISHER SCIENTIFIC INC
TWIST BIOSCIENCE CORP
ULTRAGENYX PHARMACEUTICAL INC
VERACYTE INC
VERTEX PHARMACEUTICALS INC